Canaccord Genuity maintains TransMedics Group at Buy, raises price target to $120 from $95
Canaccord Genuity kept its Buy rating on TransMedics Group and raised its price target to $120 from $95, citing a 74% potential upside from the Nov 5 close of $68.98.
How this was made

The 30-second read
Why it matters
The upgrade could attract short‑term buying interest, but without new operational news the move may be modest.
Market read
A modest but actionable catalyst for TMED investors.
What to watch
No new clinical data released; price may already reflect expectations.
Background
Analyst rating updates are common catalysts for small‑cap biotech stocks.
Market effects
May lift sentiment in the biotech/medical device sector.
Limited to US biotech investors.
Low global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- AnalystCanaccord Genuity
Equity research firm issuing the rating upgrade.
- CompanyTransMedics Group
US‑listed biotech focused on organ perfusion technologies.



